Release Date: December 11, 2025
Expiration Date: December 11, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in advanced prostate cancer. In this educational program, these experts use case-based examples to translate the latest evidence on PSMA PET and RLT—including combination strategies—into practical playbooks for selection, sequencing, toxicity monitoring, and operations, with careful attention to access and equity.
This educational activity is an archive of the live symposium held on November 13, 2025.
Target Audience
This educational activity is directed toward physicians, pathologists, advanced practice professionals, nurses, pharmacists, and other health care practitioners interested in prostate cancer.
Learning Objectives
At the conclusion of this activity, you should be better prepared
to:
- Evaluate the diagnostic and prognostic value of PSMA PET imaging and integrate imaging results into treatment planning for patients with advanced prostate cancer.
- Develop evidence-based sequencing strategies incorporating PSMA radioligands alongside AR pathway inhibitors, chemotherapy, and novel investigational agents.
- Identify real-world logistical, operational, and access-related barriers to PSMA-targeted imaging and therapy, and propose collaborative, multidisciplinary solutions to overcome them.
Scott T. Tagawa, MD, MS, FASCO, FACP
Professor of Medicine & Urology
Weill Cornell Medicine
Meyer Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Abdera, AIkido Pharma, Amgen, Bayer AG, Biohaven, Blue Earth Diagnostics, Boston Scientific, Clarity Pharmaceuticals, Clovis Oncology, Convergent Therapeutics, Daiichi Sankyo, Eisai Co, EMD Serono, Endocyte, Genentech, General Electric, Genomic Health, Immunomedics, Janssen, Karyopharm Therapeutics, Lantheus, Medivation/Astellas Pharma, Merck, Myovant Sciences, Novartis, Pfizer, POINT Biopharma, Regeneron, Sanofi, Seagen, Telix Pharmaceuticals, Tolmar, TransThera; Grant/Research Funding: AbbVie, AIQ, Ambrx, Ambrx Biopharma, Amgen, Astellas Pharma, AstraZeneca, Bayer AG, Bristol Myers Squibb, Clarity, Clovis Oncology, Endocyte, Gilead Sciences, Immunomedics, Janssen, Janux, Karyopharm Therapeutics, Medivation, Merck, Novartis, POINT Biopharma, Sanofi, Seagen, Telix; Royalty or Patent Benefits: Convergent, Gilead; Ownership interests in privately held companies: Convergent
Himisha Beltran, MD
Associate Professor of
Medicine
Director of
Translational Research
Department of Medical
Oncology
Dana-Farber Cancer
Institute
Harvard Medical School
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Bayer, Daiichi Sankyo, Merck, Novartis; Grant/Research Funding: Circle Pharma, Daiichi Sankyo, Novartis
Neeta Pandit-Taskar, MD, MBA
Professor of Radiology
Chief, Division of Nuclear Medicine
Director, Theranostics (Molecular Imaging-and
Radiopharmaceutical Therapy)
Vice Chair, Clinical and Translational Research
Department of Radiology
UPMC, University of Pittsburgh
Director, Oncologic Imaging
Hillman Cancer Center
Pittsburgh, PA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Actinium Pharmaceuticals, Blue Earth Diagnostics, Regeneron Pharmaceuticals, Telix Pharmaceuticals; Grant/Research Funding: Bristol Myers Squibb, Children’s Oncology Group (COG), Clarity Pharmaceuticals, Innervate Radiopharmaceuticals, Regeneron Pharmaceuticals
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
